TELA Bio (TELA) Operating Income Growth (3y) (2021 - 2026)

TELA Bio (TELA) Operating Income Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Abbott Laboratories 182.30 Bn 175.00 Bn 6.27 Bn -3.76%
2 Stryker 128.77 Bn 125.89 Bn 3.81 Bn 8.39%
3 Medtronic 107.99 Bn 98.77 Bn 6.41 Bn 6.17%
4 Boston Scientific 67.85 Bn 66.39 Bn 3.61 Bn 25.88%
5 Edwards Lifesciences 48.12 Bn 44.45 Bn 1.29 Bn 7.13%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 75.54%
7 GE HealthCare Technologies 27.98 Bn 25.70 Bn 1.98 Bn -2.70%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.78 Bn 20.65 Bn 2.07 Bn 34.83%
10 TELA Bio 38.25 Mn -1.29 Mn 12.52 Mn 2.20%

Historic Data

Download Data
DateValue
Mar 31, 2026 2.20%
Dec 31, 2025 11.03%
Sep 30, 2025 7.31%
Jun 30, 2025 3.92%
Mar 31, 2025 -2.08%
Dec 31, 2024 -2.96%
Sep 30, 2024 -9.07%
Jun 30, 2024 -16.53%
Mar 31, 2024 12.76%
Dec 31, 2023 -22.09%
Sep 30, 2023 -14.05%
Jun 30, 2023 -26.11%
Mar 31, 2023 -20.08%
Dec 31, 2022 -17.45%
Sep 30, 2022 -35.00%
Jun 30, 2022 -33.53%
Mar 31, 2022 -23.86%
Dec 31, 2021 -11.66%
Sep 30, 2021 -41.93%